Sacubitril And Valsartan Tablet
Product Images NDC 33342-571

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 33342-571). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

222 (Sacubitril And Valsartan Tablets 24 mg 26 mg 180s)

This text contains information about MacLEODS film-coated tablets containing 24 mg of sacubitril and 26 mg of valsartan. The usual dosage should be referred to from the prescribing information. The recommended storage temperature for the tablets is between 20 to 25°C, with excursions permitted to 15 to 30°C. It should be stored in a controlled room temperature, protected from moisture and kept out of reach of children. The tablets are manufactured by Macleods Pharma USA, Inc. for Macleods Pharmaceuticals Ltd. with a code No.: HP/152/07.*

FDA Label Image

111 (Sacubitril And Valsartan Tablets 24 mg 26 mg 60s)

This text provides information about a medication called ACL=ODY, which is a film-coated tablet containing 24 mg of sacubitril and 26 mg of valsartan. The usual dosage instructions are not available in the provided text. The medication should be stored between 20°C to 25°C, with excursions permitted between 15°C to 30°C. It is advised to keep the tablets at a controlled room temperature and out of reach of children to protect from moisture. The medication is manufactured by Macleods Pharma USA, Inc. at their facility in Baddi, Himachal Pradesh, India. The package seems to contain 60 tablets.*

FDA Label Image

777 (Sacubitril And Valsartan Tablets 49 mg 51 mg 180s)

This text is a medication label for a tablet containing 49 mg of sacubitril and 51 mg of valsartan. The standard dosage information is to be found in the prescribing information. The tablets should be stored at a temperature between 59°F to 86°F in a controlled room to protect them from moisture. The manufacturing company is Macleods Pharma USA, Inc., with a contact address in Princeton, NJ. The tablets should be kept out of the reach of children. The tablets are manufactured by Macleods Pharmaceuticals Ltd in Baddi, Himachal Pradesh, India. The product code is HP/152007.*

FDA Label Image

444 (Sacubitril And Valsartan Tablets 49 mg 51 mg 60s)

Each film-coated tablet contains 49 mg of sacubitril and 51 mg of valsartan. The usual dosage and storage instructions are provided by Pharma USA. The tablets should be stored at a temperature of 20° to 25°C (68° to 77°F) with excursions permitted up to 15° to 30°C (59° to 86°F). The product should be kept free from moisture and out of the reach of children. It is manufactured by Macleod's Pharmaceuticals Ltd.*

FDA Label Image

897 (Sacubitril And Valsartan Tablets 97 mg 103 mg 180s)

This text provides information about a medication in the form of film-coated tablets containing sacubitril and valsartan. Each tablet contains 97 mg of sacubitril and 103 mg of valsartan. The usual dosage should be referred to prescribing information. The storage instructions indicate a temperature range from 20°C to 25°C. The tablets should be protected from moisture and stored in a controlled room temperature. It also mentions the manufacturer - Macleods Pharmaceuticals USA.*

FDA Label Image

876 (Sacubitril And Valsartan Tablets 97 mg 103 mg 60s)

This text contains information about a pharmaceutical product called MACLEODS, which is a film-coated tablet containing 97 mg of sacubitril and 103 mg of valsartan. The usual dosage and storage instructions are provided along with the manufacturer details. These tablets should be stored at room temperature and protected from moisture.*

FDA Label Image

5252 (Sacubitril Valsartan 4 Figu)

The text provides detailed information on the percentage and hazard ratio of patients receiving sacubitril and valsartan compared to enalapril in different subgroups based on variables such as age, gender, weight, race, region, NYHA class, diabetes, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP level, hypertension, prior use of ACE inhibitor, ARB, aldosterone antagonist, hospitalization for heart failure, time since diagnosis of heart failure, and cause of heart failure. This data can be used to evaluate the efficacy and safety of sacubitril and valsartan in various patient populations.*

FDA Label Image

505 (Sacubitril Valsartan 6 Fig)

This text provides a detailed comparison between two treatment options, Sacubitril & Valsartan and Valsartan, based on various subgroups and characteristics such as age, gender, race, comorbidities (e.g., diabetes, AF), biomarkers (e.g., LVEF, NT-proBNP), and baseline medication use. The comparison includes data on efficacy rates and rate ratios, helping to evaluate the potential benefits of each treatment in different patient populations. It appears to be a clinical evaluation or trial study comparing the effectiveness of these two medications.*

FDA Label Image

Sacubitril-valsartan-fig-1 (Sacubitril Valsartan Fig 1)

This is a table showing the effect of Sacubitril and Valsartan on the pharmacokinetics of coadministered drugs such as Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, Sildenafil in terms of AUC and Cmax values. The table includes the geometric mean ratio and 90% CI for each drug, providing insights into potential interactions when these drugs are used together.*

FDA Label Image

Sacubitril-valsartan-fig-2 (Sacubitril Valsartan Fig 2)

FDA Label Image

333 (Sacubitril Valsartan Fig 3)

FDA Label Image

663 (Sacubitril Valsartan Fig 5)

FDA Label Image

366 (Sacubitril Valsartan Fig 7)

FDA Label Image

Str (Sacubitril Valsartan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.